GLP-1 S (Semaglutide)

Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist — a class of compounds that mimic the gut hormone GLP-1, which regulates appetite, insulin secretion, and gastric emptying. Commercially available as Ozempic (diabetes) and Wegovy (weight loss), semaglutide represents the most significant advancement in metabolic medicine in decades.

▸How It Works

GLP-1 receptors are found throughout the body — in the pancreas, gut, brain, heart, and liver. Semaglutide activates all of them:

**Appetite:** Acts on hypothalamic GLP-1 receptors to reduce hunger signals and increase satiety. Users report dramatically reduced appetite and food cravings, particularly for high-fat, high-sugar foods.

**Metabolism:** Slows gastric emptying, improving post-meal glucose control and extending satiety. Stimulates insulin secretion only when blood glucose is elevated (glucose-dependent) — minimizing hypoglycemia risk.

**Weight Loss:** Clinical trials (SUSTAIN, STEP) show 15-20% body weight reduction over 68 weeks — the most effective pharmacological weight loss ever demonstrated in controlled trials.

▸Beyond Weight

Semaglutide has shown benefits beyond weight loss:

→20% reduction in cardiovascular events in the SELECT trial

→Reduced liver fat in NASH

→Potential neuroprotective effects (GLP-1 receptors in the brain)

▸Research Context